Redmile Group’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-8,244,896
| Closed | -$155M | – | 86 |
|
|
2019
Q3 | $155M | Hold |
8,244,896
| – | – | 5.2% | 5 |
|
|
2019
Q2 | $97M | Hold |
8,244,896
| – | – | 2.75% | 9 |
|
|
2019
Q1 | $113M | Buy |
8,244,896
+1,739,130
| +27% | +$22.5M | 3.29% | 7 |
|
|
2018
Q4 | $66.7M | Hold |
6,505,766
| – | – | 2.68% | 12 |
|
|
2018
Q3 | $108M | Hold |
6,505,766
| – | – | 3.33% | 8 |
|
|
2018
Q2 | $103M | Hold |
6,505,766
| – | – | 3.49% | 7 |
|
|
2018
Q1 | $82.6M | Hold |
6,505,766
| – | – | 3.19% | 7 |
|
|
2017
Q4 | $74.5M | Buy |
6,505,766
+29,000
| +0.4% | +$324K | 3.24% | 6 |
|
|
2017
Q3 | $79.3M | Buy |
6,476,766
+4,252,955
| +191% | +$44.3M | 3.91% | 6 |
|
|
2017
Q2 | $25.5M | Buy |
2,223,811
+313,925
| +16% | +$5.8M | 1.55% | 25 |
|
|
2017
Q1 | $39.7M | Buy |
1,909,886
+989,336
| +107% | +$21.9M | 2.58% | 13 |
|
|
2016
Q4 | $19.1M | Buy |
920,550
+218,011
| +31% | +$5.67M | 1.65% | 21 |
|
|
2016
Q3 | $23M | Buy |
+702,539
| New | +$21.4M | 1.83% | 21 |
|
Redmile Group's ALDR Position: Q4 2019 in Review
Redmile Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 8,244,896 shares — an estimated $155M sold.
Redmile Group first reported a position in ALDR in Q3 2016 and held it in 13 quarters. The position peaked at $155M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Redmile Group reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Redmile Group sold 8,244,896 Alder Biopharmaceuticals shares in Q4 2019, an estimated $155M.
- Redmile Group first reported a position in Alder Biopharmaceuticals in Q3 2016 and held it in 13 quarters.
- Redmile Group's Alder Biopharmaceuticals position peaked at $155M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.